How to Choose a Tracking App for Your Peptide Protocol in 2026
7 min read
CTO & Co-Founder of miora. Stanford Biodesign, ex-Tesla.
There are a dozen apps that will let you log a peptide dose. Three of them are actually built for a real protocol. The rest are repurposed habit trackers or pill reminders. This guide walks the six things that matter, the questions to ask before you commit, and how miora handles each one in iMessage instead of an app.
Topics on this page
Most peptide trackers fail in month three because the logging burden is too high to sustain. The right tool reduces logging to under thirty seconds per dose.
Reconstitution math errors are the most common dosing mistake. A tracker that does not auto-calculate units from concentration is not built for serious protocols.
Symptom logging is where the protocol-attributable signal lives. Without a six-dimension daily rubric you will miss mood and recovery drift entirely.
If you are running a peptide protocol that is more involved than a single daily peptide and a hope, you have already hit the limits of the spreadsheet. The reconstitution math is annoying. The injection-site rotation gets forgotten. The cycle dates drift. Symptoms go unlogged for two weeks at a time, then a side effect shows up that you cannot trace back to anything. This is the point where most people start looking for an app - and most apps are not designed for the protocol they are actually running. This guide is the honest list of what matters, what does not, and what to ask before you put your bloodwork in someone else's database.
The single most common protocol-tracking failure is losing the cycle. You start BPC-157 on a Tuesday, you tell yourself you are running eight weeks on, four weeks off. By week six, you cannot remember whether you started on the 14th or the 21st. The off-cycle date drifts. You finish on a different week than you intended. The protocol effectiveness becomes a guess.
A real peptide tracker stores three things every injection: the date and time, the compound, the dose, the injection site, and the week of the cycle. The cycle week is the one most apps miss. A generic medication reminder will tell you 'inject at 8 a.m.'; it will not tell you 'this is week 5 of 8 of your BPC-157 cycle, next planned washout starts Monday the 22nd.'
The cycle awareness has downstream effects. Stacking compounds (a growth-hormone-axis stack like CJC-1295 plus ipamorelin alongside a BPC-157 healing cycle) requires the tracker to know which compound is in which week. The interaction risks - and the dosing decisions - depend on the cycle position. Ask any app you are considering: can it track three concurrent cycles with different durations and washout periods? If not, you will be running the math manually by month two.
The second most common dosing mistake is unit math. You reconstitute a 5 mg vial with 2 mL of bacteriostatic water; you want a 250 mcg dose; your insulin syringe is marked in units. The math is straightforward but it is also done at 7 a.m. with caffeine half-onboarded, and the failure mode is consistent across the community: dose drifts in either direction over a multi-week cycle.
A purpose-built tracker takes the inputs (vial mg, reconstitution volume in mL, target dose in mcg) and tells you the units on the syringe. It stores the reconstitution date so you also know how many days the bac water has been in the vial - peptide stability is a separate concern that most apps ignore but matters for a serious protocol.
Edge cases the tooling should handle: dual-pathway stacks where the same syringe carries two compounds; subcutaneous-versus-intramuscular dose splits; vial-to-pen conversions for tirzepatide (a common task once people start sourcing compound to save cost); and dose tapering schedules where the target mcg changes weekly. None of these are exotic; all of them are the things a generic pill reminder gets wrong.
The signal that determines whether a protocol is working is not the visible result. It is the daily symptom trend. Trackers that only log injections - even cycle-aware ones - miss the entire mood, energy, libido, and recovery drift that the community keeps surfacing in long Reddit threads. A six-dimension 1-to-5 daily rubric (energy, drive, libido, irritability, social motivation, anhedonia) takes ten seconds to log and catches patterns that no single-dimension mood app does.
For peptide-specific symptoms - injection-site reactions, sleep disruption on growth-hormone-axis peptides, GI side effects on GLP-1s - the rubric needs to be flexible enough to add a compound-specific dimension when relevant. A serious tracker lets you append, say, 'morning fasted hunger 1-5' for the GLP-1 weeks and remove it during washout. Generic symptom apps do not have this flexibility.
The cross-reference matters more than the log itself. A 2-out-of-5 anhedonia score in the third week of a stable dose with normal sleep and recovery is a different signal than the same score after a bad week of sleep. The tracker that surfaces the cross-reference - mood data alongside sleep, HRV, training load, and dose schedule - is the one that actually changes decisions. The six-dimension symptom rubric is detailed here.
A peptide protocol that runs longer than a quarter without lab work is operating on vibes. The compounds most worth tracking - growth-hormone-axis peptides, GLP-1s, certain healing peptides at higher doses - have measurable effects on IGF-1, fasting glucose, lipids, liver enzymes, and inflammatory markers. The quarterly panel is the only data that closes the loop between 'I feel like this is working' and 'this is actually doing what it is supposed to.'
Lab integration in a tracker means three things: the app can ingest a lab PDF or LabCorp/Quest portal export, it can chart trends across panels rather than treating each one as isolated, and it can flag values that crossed reference ranges since the last panel. The flag is what matters. An IGF-1 that went from 180 to 280 in one quarter is meaningful even if both numbers are within the lab's reference range, because the trend tells you the protocol is dose-responsive.
This is also where the standalone-app failure mode shows up. A typical workflow without integration: get labs on Friday, get the PDF Monday, intend to review it that week, forget, find it three months later when the next panel arrives, never compare them side by side. A tracker that auto-ingests the panel the day it arrives and surfaces the trend in the next message is the only version of this that survives a busy week.
Peptides occupy a regulatory grey zone in the United States and most jurisdictions. Many of the compounds people are running - BPC-157, TB-500, ipamorelin, AOD-9604, retatrutide - are not FDA-approved for the use being made. Some are research peptides. Some are compounded by pharmacies that may or may not exist in six months. Your log of what you injected, when, and at what dose is sensitive in a way that a fitness app log is not.
Three privacy questions worth asking any app: where is the data stored, can it be exported and deleted on demand, and does the company sell or share aggregated data with any third party. The honest answer for most consumer apps is 'on our servers, partial export only, yes we share aggregated data.' That is fine for a habit tracker. It is not fine for a peptide log.
miora's approach is to keep the log in your iMessage thread - on your phone, end-to-end encrypted in transit, never on a marketing-data server. The protocol summaries that miora generates for clinician sharing are explicit exports, not automatic uploads. The default is private; sharing is a deliberate act.
The single best predictor of whether a tracker will work for you is whether you will still be using it in month six. Most peptide protocols are not three weeks; they are three to twelve months with washouts. The logging burden compounds.
Three failure patterns kill peptide trackers in month two or three. Pattern one: the app requires opening, navigating, and logging in three taps minimum. By week eight you are doing two of the three and the data integrity collapses. Pattern two: the daily symptom log takes more than thirty seconds. Pattern three: the user has to look at a chart to know whether anything is changing. If the trend does not surface itself - if you have to go find it - you will not.
Test the app on a Wednesday in week eight, not on the day you download it. The download-day experience is misleading. The eighth-Wednesday experience is the only one that matters.
The reason miora is built as an iMessage agent rather than a standalone app is that the iMessage thread solves the sustainability problem first. There is no app to open. You text the dose - 'BPC 500 mcg sub-q, right glute' - and miora logs it, calculates the cycle week, confirms the next planned washout, and replies in under three seconds.
Cycle-aware log: yes, multi-cycle, with washout reminders. Dose calculation: yes, with reconstitution date and vial-stability awareness. Symptom rubric: yes, the six-dimension daily check sent each evening, with a free-text option if you prefer prose. Lab integration: yes, drop a LabCorp or Quest PDF into the thread and miora parses the panel and flags trend shifts. Privacy: the log lives in your iMessage thread, not in a marketing database; export and deletion on demand. Sustainability: under thirty seconds per dose, no app to keep open, weekly summary that surfaces drift before you have to ask.
For people running stacks alongside a wearable - WHOOP for recovery, Apple Health for sleep, Withings for daily weight - the integration is one of the things that makes the cross-reference work. The WHOOP integration guide explains how miora cross-references HRV trends against dose timing.
Before you give an app your protocol details, walk through these six questions. The right answer to each is the same regardless of which tool you pick.
Can it track three concurrent cycles with different durations? If not, stacking is broken from day one.
Does it auto-calculate units from vial mg, reconstitution volume, and target mcg? If you are doing this math manually, you will get it wrong at least once.
Does it include a multi-dimension daily symptom rubric, not just an injection log? Mood and recovery drift live in the symptom trend, not the injection record.
Can it ingest a lab PDF and chart the trend across panels? The quarterly panel is the only data that closes the loop.
Where is the data stored, can it be deleted on demand, and is any data shared with third parties? Peptide data is sensitive; default-private is the only acceptable answer.
What is the logging burden per dose, and what is it in month six? Test it on a bad day in week eight, not on the download-day demo.
Most generic apps will fail at least three of the six. A purpose-built peptide tracker should pass all six. miora was built around these six requirements specifically; if you are running a serious protocol, this is the kind of decision worth ten minutes of due diligence.
Two important boundaries.
This guide does not recommend specific compounds, doses, sources, or compounding pharmacies. miora does not prescribe, source, or suggest peptides. If you are deciding whether to start a protocol or which compound to run, that conversation belongs with a qualified clinician who can review your labs, history, and goals - not with an app. This content is for informational purposes only and is not medical advice. Peptides are not FDA-approved supplements; many of the compounds discussed are in a regulatory grey zone and require clinician supervision.
The guide also does not promise specific outcomes. The right tracking tool helps you run a better protocol - one with cleaner data, earlier flags, and a closed loop with your clinician. It does not change the underlying biology or guarantee that any specific protocol will produce a specific result. The point is to be in a position to make informed decisions with structured data, not to be sold the tool that makes the data look best.
93
